LifeMD Launches Proprietary Over-the-Counter Skincare Line for Women, Expanding Teledermatology Offerings
NavaMD’s clinically studied, OTC skincare platform is protected by a global intellectual property portfolio and $50+ Million of third-party capital invested in R&D, clinical research, and manufacturing.
NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the launch of its clinically studied, over-the-counter (OTC) clinical skincare product line for women.
NavaMD™ is revolutionizing dermatology by making it possible to visit a dermatologist anywhere, anytime. Its new OTC skincare line is supported by over 35 patents, rigorous clinical testing, and several peer-reviewed medical publications. Its proprietary enzyme technology, Aquabeautine XL®*, relies on a groundbreaking mechanism to target and dissolve dead skin cells while leaving healthy cells untouched. Aquabeautine XL enables effective skin rejuvenation without the potential irritation often seen in other types of exfoliants. The OTC line consists of a cleanser, serum, moisturizer, and eye cream – all safe for any skin type. The products are natural, non-toxic, dermatologist-tested, hypoallergenic, and effective on their own or safely paired with any of NavaMD’s prescription treatments.
“In dermatology, we know there is no 'one size fits all' approach to treating patients, even within specific skin concerns and/or conditions. The key is to combine timely and supportive care from great doctors with effective personalized prescription treatments and scientifically supported over-the-counter products,” said Dr. Matthew Zipoli, medical chair of NavaMD.
“NavaMD’s Aquabeautine XL product line is one of the most compelling OTC skincare offerings I have seen in over 20 years of practicing dermatology,” Zipoli said.
NavaMD offers women a new way to access exceptional dermatology. With its team of licensed board-certified dermatologists and physicians, NavaMD focuses on treating a range of prevalent skincare concerns and diseases, such as acne, rosacea, and aging skin—with future rollouts planned across other dermatological treatment areas. By leveraging proprietary technology from its parent company, LifeMD, patients have access to and benefit from a suite of world-class virtual dermatologists and physicians, custom treatment plans, and ongoing medical support and follow-ups—all from the comfort of home.
“In-licensing and further developing proprietary and clinically studied OTC products that support our telehealth and pharmacy offerings remains a key part of LifeMD’s long-term strategy,” said LifeMD’s founder and CEO, Justin Schreiber. “NavaMD's expanded portfolio follows this model and highlights the inherent synergies of our approach.”
NavaMD offers patients a complete teledermatology experience, including a complementary dermatology consultation and specialized treatment plans along with a free 30-day trial of custom prescription formulas. Patients can discuss their treatment and progress at any time with their assigned physician or any of NavaMD’s patient support team members. Visit to learn more.
About LifeMD
LifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men’s and women’s health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, affiliated 50-state medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
*Aquabeautine XL® is a registered trademark of Aqua Bio Technology ASA.
Company Contact
LifeMD, Inc.
Marc Benathen, CFO
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
Media Contact
Eric Herman
Kivvit
